Pancreatic cancer

Clinical Trials

Mayo Clinic physicians recently completed a clinical trial comparing the standard Whipple operation with extended lymphadenectomy.

Below is a list of Pancreatic cancer clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

AZD0530 in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
OBJECTIVES: Primary - To determine the 6-month survival of biomarker-positive patients with previously treated metastatic pancreatic cancer receiving AZD0530. - To determine the adverse events of this drug in these patients. Secondary - To evaluate the response rate in patients treated with this drug.
Read more

Biospecimen Resource for Familial Pancreas Research, a Data and Tissue Registry (also known as a bio-repository, bio-bank, data and tissue database, data and tissue bank, etc.) to Help Advance Research in Familial Pancreas Disease.
The research staff is collecting clinical and family histories, blood and/or tissue samples from family members of patients diagnosed with pancreatic diseases, including pancreatic cancer and melanoma. This will help the researchers to learn whether inherited factors increase the risk of pancreatic diseases, pancreatic cancer, or other cancers.
Read more

Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (also known as a bio-repository, bio-bank, data & tissue database, data & tissue registry, etc.) to Help Advance Research in Pancreas Disease.
This study is being done to develop better ways to screen people at risk for pancreatic conditions, including pancreatic cancer. It is being done to try to find new genes or substances that may make some people more likely to develop pancreatic conditions, and to find agents that may help to prevent, treat, or cure them.
Read more

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma
OBJECTIVES: - To collect clinical history, family history, and blood and/or tissue samples from family members of patients diagnosed with pancreatic diseases, pancreatic cancer, or melanoma. - To learn whether inherited factors increase the risk of pancreatic diseases, pancreatic cancer, or other cancers.
Read more

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
OBJECTIVES: Primary - To collect clinical data and family histories and blood and/or tissue samples from patients diagnosed with pancreatic diseases, including pancreatic cancer, for use in future studies. - To collect information regarding food preparation and intake in these patients.
Read more

Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
The overall goal of this study is to test a technique that in the future may allow endoscopic detection of pancreatic neoplasia. The study is a single group, prospective, open label pilot study designed to assess the feasibility and efficacy of 4D-ELF in detecting EIBS in peri-ampullary duodenal mucosa in pancreatic cancer patients compared to control patients.
Read more

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
OBJECTIVES: Primary - To determine the maximum tolerated dose of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 with or without gemcitabine hydrochloride in patients with unresectable solid tumors. Secondary - To describe the adverse events profile associated with these treatment regimens.
Read more

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OBJECTIVES: Primary - To estimate the proportion of patients with resectable adenocarcinoma of the pancreas alive at 2 years from the date of study registration after treatment with neoadjuvant and adjuvant gemcitabine hydrochloride and erlotinib hydrochloride plus pancreatectomy.
Read more

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
OBJECTIVES: Primary - To determine whether the addition of erlotinib hydrochloride to adjuvant chemotherapy comprising gemcitabine hydrochloride improves survival as compared to gemcitabine hydrochloride alone following R0 or R1 resection in patients with pancreatic adenocarcinoma.
Read more

Immunotherapy Study for Surgically Resected Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease. The primary reason for this is that the disease is typically without symptoms until significant local and/or distant spread has occurred and is often beyond the chance for cure at the time of the diagnosis.
Read more

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
A Phase III, open-label randomized, multicenter trial to compare ABI-007(Albumin-bound Paclitaxel)in combination with gemcitabine administered weekly to standard treatment (gemcitabine monotherapy) with respect to overall survival, objective tumor response rate and PFS in patients diagnosed with metastatic adenocarcinoma of the pancreas.
Read more

Supplemental Method of Controlling Pain in Pancreatic Cancer Patients
The purpose of this trial is to determine the effectiveness of celiac plexus neurolysis as an adjunct to standard medical therapy for pain control in patients with unresectable pancreatic cancer and moderate to severe pain.
Read more